OncoCyte Corporation (OCX)
| Market Cap | 36.62M |
| Revenue (ttm) | 1.38M |
| Net Income (ttm) | -40.86M |
| Shares Out | 13.36M |
| EPS (ttm) | -5.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165 |
| Open | 2.900 |
| Previous Close | 2.930 |
| Day's Range | 2.910 - 3.080 |
| 52-Week Range | 2.080 - 4.900 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 4.06 (+38.57%) |
| Earnings Date | May 15, 2024 |
About OCX
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design an... [Read more]
Financial Performance
In 2023, OncoCyte's revenue was $1.50 million, an increase of 56.89% compared to the previous year's $958,000. Losses were -$28.72 million, -60.88% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OCX stock is "Buy." The 12-month stock price forecast is $4.06, which is an increase of 38.57% from the latest price.
News
Oncocyte Reports First Quarter 2024 Financial Results
IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.
Oncocyte Reports Full Year 2023 Financial Results
IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2...
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal
Oncocyte Announces 1-For-20 Reverse Stock Split
IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 revers...
Oncocyte Begins Manufacturing Transplant Blood Test
Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics comp...
Oncocyte Corporation to Present at the LD Micro Invitational XIII
Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevar...
Oncocyte Reports First Quarter 2023 Financial Results
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023...
Oncocyte To Announce First Quarter 2023 Financial Results
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on...
Oncocyte Presents New Data at AACR
IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at t...
Oncocyte Announces Reduction in Force
IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforc...
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying ...
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchang...
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earning...
Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 finan...
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Offi...
Oncocyte Completes Razor Genomics Transaction
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy
Oncocyte cuts 40% of staff
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its...
Oncocyte Announces Initiatives to Focus Corporate Strategy
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte's workforce t...
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
Oncocyte Announces Executive Leadership Changes
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
Oncocyte Reports Third Quarter 2022 Financial Results
IRVINE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
Oncocyte to Announce Third Quarter 2022 Financial Results
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...
Oncocyte Announces Five-Year VA Contract for DetermaRx
IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights th...